Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase II Trial of Cabozantinib and Erlotinib for Patients with EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Summary

The purpose of this phase II trial is to evaluate the safety and effectiveness of cabozantinib and erlotinib among patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma.

General Information

NCT#: NCT03213626
Study ID: IUSCC-0597
Trial Phase: Phase II

Trial Sponsor: Exelixis, Inc., Indiana University
Therapies Used in This Trial: Erlotinib, Cabozantinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search